Intensive Cardiac Care Unit, Centro CardiologicoMonzino, I.R.C.C.S., Milan, Italy.
Catheter Cardiovasc Interv. 2015 Feb 15;85(3):345-51. doi: 10.1002/ccd.25694. Epub 2014 Oct 24.
We investigated the use of a 3-hr treatment with hemodiafiltration, initiated soon after emergency or urgent coronary angiography in acute coronary syndrome (ACS) patients with associated severe renal and cardiac dysfunction.
Patients with ACS and severe combined renal and cardiac dysfunction have a particularly high mortality risk. In them, the ideal strategy to both optimize treatment of coronary disease and minimize renal injury risk is currently unknown.
This was an interventional study. ACS patients (STEMI and NSTEMI) with associated severe renal (eGFR ≤30 ml/min/1.73 m(2) ) and cardiac (LVEF ≤40%) dysfunction, admitted at La Spezia Hospital <24 hr from symptoms onset, underwent a prophylactic 3-hr hemodiafiltration treatment, which was started soon after urgent or emergency coronary procedure. Controls were patients matched for age, gender, Mehran's risk score, and kind of ACS, admitted at the Centro Cardiologico Monzino Milan. In-hospital and 1-year outcomes were evaluated.
Sixty patients (30% STEMI), 30 hemodiafiltration-treated patients and 30 controls, with similar baseline characteristics, were included. In-hospital and cumulative 1-year mortality rates were significantly lower in hemodiafiltration-treated patients than in controls (3% vs. 23%; P = 0.05, and 10% vs. 53%; P < 0.001, respectively). Moreover, they had a lower incidence of severe AKI (10% vs. 40%; P = 0.015) and lower need for rescue renal replacement therapy during hospitalization (7% vs. 27%; P = 0.04).
Our pilot study suggests that, in ACS patients with severe renal and cardiac insufficiency, treatment with an aggressive prophylactic hemodiafiltration session after urgent or emergency coronary angiography seems to be associated with a relevant improvement in survival.
我们研究了在急性冠状动脉综合征(ACS)患者中,在紧急或急诊冠状动脉造影后立即开始 3 小时血液透析滤过治疗,以改善合并严重肾功能和心功能障碍的患者的预后。
ACS 合并严重肾功能和心功能障碍的患者死亡率极高。目前尚不清楚在这类患者中,同时优化冠状动脉疾病治疗和降低肾脏损伤风险的最佳策略。
这是一项干预性研究。莱切医院在症状发作后 24 小时内收治的 ACS 患者(STEMI 和 NSTEMI)合并严重肾功能(eGFR≤30ml/min/1.73m²)和心功能障碍(LVEF≤40%),接受预防性 3 小时血液透析滤过治疗,在紧急或急诊冠状动脉手术后立即开始。对照组为年龄、性别、Mehran 风险评分和 ACS 类型匹配的米兰 Centro Cardiologico Monzino 医院收治的患者。评估住院期间和 1 年的结局。
共纳入 60 例患者(30%为 STEMI),其中 30 例接受血液透析滤过治疗,30 例为对照组,两组患者基线特征相似。血液透析滤过治疗组患者住院期间和 1 年累积死亡率均显著低于对照组(3%比 23%;P=0.05 和 10%比 53%;P<0.001)。此外,血液透析滤过治疗组患者严重急性肾损伤发生率较低(10%比 40%;P=0.015),住院期间需要挽救性肾脏替代治疗的比例也较低(7%比 27%;P=0.04)。
本研究初步结果表明,在 ACS 合并严重肾功能和心功能不全的患者中,在紧急或急诊冠状动脉造影后立即进行积极的预防性血液透析滤过治疗,可能会显著改善生存率。